| External factors: | Rapamycin |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay//Cell morphological analysis |
| Description: | HUVECs that were prolonged treated with low dose rapamycin (18 days in culture) and then sub-cultured in the absence of rapamycin until passage 25–27 displayed normal cell morphology whereby the cellswere relatively smaller in size compared to the larger cell size and higher granularity of the vehicle-treated senescent cells. There was also a significant decrease in SA-β gal activity in these cells,whereby, the HUVECs culture treated with 1 nM rapamycin consisted of only 18.7% SA-β gal-positive cells compared to the higher percentage of SA-β gal-positive cells in the vehicle control cells. |
| Regulatory pathway: | MTORC1 |
| R-EF-Pathway: | Downregulation |
| Official symbol(s): | CASTOR1 |
| Pathway experiment: | Western blot |
| Pathway description: | The expression of phosphorylated MTOR (p-MTOR), which is the main component of MTORC1, was significantly suppressed at 0.5 nM rapamycin. Moreover, its downstream proteins, phosphorylated ribo-somal protein S6 (p-RPS6) and phosphorylated 4EBP1 (p-4EBP1) were significantly down-regulated with 0.5 nM rapamycin and at higher doses, which confirmed MTORC1 attenuation by low dose rapamycin treatment. |
Annotation: